Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
AR Ibrahim, C Paliompeis, M Bua… - Blood, The Journal …, 2010 - ashpublications.org
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib
and a second tyrosine kinase inhibitor but were still in first chronic phase and identified
prognostic factors for response and outcomes. The achievement of a prior cytogenetic
response on imatinib or on second-line therapy were the only independent predictors for the
achievement of complete cytogenetic responses on third-line therapy. Younger age and the
achievement of a cytogenetic response on second line were the only independent predictors …
and a second tyrosine kinase inhibitor but were still in first chronic phase and identified
prognostic factors for response and outcomes. The achievement of a prior cytogenetic
response on imatinib or on second-line therapy were the only independent predictors for the
achievement of complete cytogenetic responses on third-line therapy. Younger age and the
achievement of a cytogenetic response on second line were the only independent predictors …
[HTML][HTML] Efficacy of tyrosine kinase inhibitors (TKIs) as third line therapy in patients with chronic myeloid leukaemia in chronic phase who have failed two prior TKIs
AR Ibrahim, M Bua, JS Khorshad, D Milojkovic… - Blood, 2010 - Elsevier
Abstract 2274 Patients with CML in chronic phase who have failed imatinib therapy are
commonly treated with dasatinib or nilotinib, but a significant proportion fail to respond or
relapse in which case they are often treated with the other tyrosine kinase inhibitor (TKI) that
they had not yet received. We report here the largest series of CML patients in CP treated
with a third line TKI after failing both imatinib and another TKI. We enrolled 26 patients. The
median age was 64 years and 54% were male. 20 patients had received dasatinib and 6 …
commonly treated with dasatinib or nilotinib, but a significant proportion fail to respond or
relapse in which case they are often treated with the other tyrosine kinase inhibitor (TKI) that
they had not yet received. We report here the largest series of CML patients in CP treated
with a third line TKI after failing both imatinib and another TKI. We enrolled 26 patients. The
median age was 64 years and 54% were male. 20 patients had received dasatinib and 6 …
以上显示的是最相近的搜索结果。 查看全部搜索结果